88 related articles for article (PubMed ID: 7703570)
1. [Combination of etoposide, cisplatin and ifosfamide (VPH) in the salvage chemotherapy of relapsing or refractory aggressive malignant lymphoma. Study of 51 patients].
Eghbali H; Catry-Thomas I; Soubeyran P; Bonnel C; Hoerni B
Bull Cancer; 1994 Sep; 81(9):800-7. PubMed ID: 7703570
[TBL] [Abstract][Full Text] [Related]
2. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
3. Salvage chemotherapy with dexamethasone, etoposide, ifosfamide and cisplatin (DVIP) for relapsing and refractory non-Hodgkin's lymphoma.
Lazar AD; Shpilberg O; Shaklai M; Bairey O
Isr Med Assoc J; 2009 Jan; 11(1):16-22. PubMed ID: 19344007
[TBL] [Abstract][Full Text] [Related]
4. DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL).
Coleman M; Leonard J; Shuster MW; Kaufman TP
Eur J Haematol Suppl; 2001 Jul; 64():41-5. PubMed ID: 11486401
[TBL] [Abstract][Full Text] [Related]
5. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[TBL] [Abstract][Full Text] [Related]
6. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
Zinzani PL; Tani M; Molinari AL; Stefoni V; Zuffa E; Alinari L; Gabriele A; Bonifazi F; Salvucci M; Tura S; Baccarani M
Haematologica; 2002 Aug; 87(8):816-21. PubMed ID: 12161357
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of DICE (dexamethasone, etoposide, ifosfamide, and cisplatin) regimen on recurrent and refractory non-Hodgkin's lymphoma].
Bo LJ; Liang AB; Liu B; Chen YH; Wang F; Jin XP
Ai Zheng; 2006 Dec; 25(12):1553-6. PubMed ID: 17166385
[TBL] [Abstract][Full Text] [Related]
8. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
[TBL] [Abstract][Full Text] [Related]
9. Combination of ifosfamide, methotrexate, and etoposide (IMVP) as a salvage therapy for relapsed and refractory aggressive non-Hodgkin lymphoma: retrospective study.
Aurer I; Duraković N; Radman I; Nemet D; Zupancić-Salek S; Kovacević-Metelko J; Bogdanić V; Sertić D; Mrsić M; Mikulić M; Labar B
Croat Med J; 2002 Oct; 43(5):550-4. PubMed ID: 12402394
[TBL] [Abstract][Full Text] [Related]
10. Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma.
Musolino A; Perrone MA; Michiara M; Delnevo D; Franciosi V; Di Blasio B; Ceci G; Camisa R; Ardizzoni A; Cocconi G
Cancer; 2005 May; 103(10):2109-17. PubMed ID: 15803492
[TBL] [Abstract][Full Text] [Related]
11. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
Kleiner S; Kirsch A; Schwaner I; Kingreen D; Schwella N; Huhn D; Siegert W
Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474
[TBL] [Abstract][Full Text] [Related]
12. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
[TBL] [Abstract][Full Text] [Related]
13. [Salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin's lymphoma with a combination of dexamethasone, etoposide, ifosfamide and carboplatin].
Okamoto M; Maruyama F; Tsuzuki M; Nomura T; Miyazaki H; Wakita M; Kojima H; Sobue R; Matsui T; Ino T
Rinsho Ketsueki; 1994 Jul; 35(7):635-41. PubMed ID: 8065017
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza.
Zanetta G; Fei F; Mangioni C
Semin Oncol; 2000 Feb; 27(1 Suppl 1):23-7. PubMed ID: 10697040
[TBL] [Abstract][Full Text] [Related]
15. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
16. High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma.
Salar A; Martino R; Perea G; Ribera JM; López-Guillermo A; Guardia R; Escoda L; Altés A; Sierra J; Montserrat E
Haematologica; 2002 Oct; 87(10):1028-35. PubMed ID: 12368156
[TBL] [Abstract][Full Text] [Related]
17. Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma.
Mayer J; Vásová I; Korístek Z; Navrátil M; Klabusay M; Doubek M; Vorlícek J; Cernilová I; Vodvárka P; Petráková K
Eur J Haematol Suppl; 2001 Jul; 64():21-7. PubMed ID: 11486396
[TBL] [Abstract][Full Text] [Related]
18. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival.
van Besien K; Rodriguez A; Tomany S; Younes A; Donato M; Sarris A; Giralt S; Mehra R; Andersson B; Gajewski J; Champlin R; Cabanillas F
Bone Marrow Transplant; 2001 Feb; 27(4):397-404. PubMed ID: 11313669
[TBL] [Abstract][Full Text] [Related]
20. Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
Clavio M; Garrone A; Pierri I; Michelis GL; Balocco M; Albarello A; Varaldo R; Canepa P; Miglino M; Ballerini F; Canepa L; Gobbi M
Oncol Rep; 2005 Oct; 14(4):933-40. PubMed ID: 16142354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]